Amedisys chief accounting officer sells $187,833 in stock

Published 06/03/2025, 22:04
Amedisys chief accounting officer sells $187,833 in stock

In a recent transaction, Allyson Guidroz, the Chief Accounting Officer of Amedisys Inc . (NASDAQ:AMED), sold 2,041 shares of the company’s common stock. The sale, executed on March 4, 2025, was conducted at an average price of $92.03 per share, generating a total of $187,833. The transaction comes as Amedisys, with a market capitalization of $3.54 billion, trades near its 52-week high of $98.95. Following this transaction, Guidroz holds 8,761 shares directly. Additionally, there is a separate indirect holding of 1.5 shares through a 401(k) plan. These transactions were detailed in a Form 4 filing with the Securities and Exchange Commission. According to InvestingPro analysis, Amedisys currently trades at a P/E ratio of 69.9, though the stock shows historically low price volatility. InvestingPro’s Fair Value model suggests the stock may be slightly undervalued, with additional insights available through their premium service.

In other recent news, Amedisys Inc. has experienced significant developments regarding its merger with UnitedHealth Group (NYSE:UNH). The merger agreement has been extended to December 31, 2025, amid scrutiny from the U.S. Department of Justice, which raised antitrust concerns. This extension includes an increased break fee, now set between $275 million and $325 million, if UnitedHealth fails to divest certain assets by May 1, 2025. Meanwhile, RBC Capital Markets continues to maintain an Outperform rating on Amedisys, reinforcing confidence in the merger’s alignment with UnitedHealth’s strategic goals. Additionally, Amedisys has terminated its agreement to sell certain home health centers to VCG Luna, influenced by legal challenges and antitrust concerns. At the company’s recent annual meeting, shareholders elected nine directors and ratified KPMG LLP as independent accountants. These developments are closely monitored by investors, given their potential impact on Amedisys’s business strategy and operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.